Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
For use during the induction and maintenance of general anesthesia.
Nationwide Children's Hospital, Columbus, Ohio, United States
Mansoura University Hospitals, Mansoura, DK, Egypt
Department of Anesthesiology, The Second Xiangya Hospital, Changsha, Hunan, China
Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain
Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of
Medical University of Gdansk, Gdansk, Poland
Oslo University Hospital, Oslo, Norway
Konkuk University Medical Center, Seoul, Korea, Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.